LINQ for impEdance meAsuremeNt While Off From HF Medication Study (LEAN HF)

Medtronic

Status and phase: Unknown; Phase 4

Conditions: Heart Failure

Treatments: Drug: Diuretic and Medication Suspension (DMS); Drug: Diuretic Suspension (DS); Drug: Diuretic Increase (DI)

Study type: Interventional

Funder types: Industry

Identifiers

NCT03245281

MDT16014

Details and patient eligibility

About

The purpose of this non-randomized, cross-over, unblinded, single-center feasibility study is to assess the sensitivity of the LINQ ICM to measure derived-subcutaneous impedance in patients with heart failure during periods when diuretics and/or HF-medication consumption is increased or suspended for 48 hours (up to 72 hours at physician discretion) and to collect safety information related to HF status and to medication consumption changes.

Full description

Up to 30 subjects with a clinical diagnosis of Heart Failure will be enrolled in the study. It is expected that the subjects will be enrolled over a period of approximately 6 months.

3 follow up visits are planned at 2, 4 and 6 months (+/- one week) following the LINQ ICM implant.

The total expected duration of the study is of about 1 year. According to the enrolment chronological order, each subject will be allocated to Diuretic Suspension group (DS), Diuretic Increase (DI) or Diuretic+MRA medication Suspension (DMS), which will define the medication regimen before the follow-up visit.

Primary objective of the study is detecting the variation of impedance magnitude and the time of occurrence after medication regimen changes will be evaluated at each follow-up.

Enrollment: 30 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinical Diagnosis of Heart Failure
• Plasma NT-proBNP (>250ng/L in SR and >1,000ng/L in AF)
• LVEF <50% measured in the year before enrolment
• Treated routinely with a daily dose of loop diuretic
• Receiving other guideline-indicated therapy for heart failure
• Willing to sign the informed consent form.
• Greater than 18 years of age.

Exclusion criteria

• Pregnant patients (all females of child-bearing potential must have a negative pregnancy test before LINQ ICM implant)
• eGFR <30 ml/minute.
• Any concomitant condition which in the opinion of the investigator would not allow a safe participation in the study.
• Patients with implanted pacemakers or defibrillators
• Severe aortic or mitral valve disease
• Breathlessness at rest or on minor exertion.
• Chest pain at rest or on mild or moderate exertion.
• Patients deemed too unstable to miss 48 hours of heart failure treatment
• Enrolled in another study that could confound the results of this study, without documented pre-approval from Medtronic study manager

Trial design

Primary purpose: Other

Allocation: Non-Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

30 participants in 3 patient groups

Diuretic Suspension (DS)

Experimental group

Treatment:

Drug: Diuretic Suspension (DS)

Diuretic Increase (DI)

Experimental group

Treatment:

Drug: Diuretic Increase (DI)

Diuretic and Medication Suspension (DMS)

Experimental group

Treatment:

Drug: Diuretic and Medication Suspension (DMS)